RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pieris Pharmaceuticals Stock

Pieris Pharmaceuticals Employees 2024

Pieris Pharmaceuticals Employees

114

Ticker

PIRS

ISIN

US7207951036

WKN

A12G4Q

In 2024, Pieris Pharmaceuticals employed 114 people, a 0% change from the 114 number of employees in the previous year.

Pieris Pharmaceuticals Aktienanalyse

What does Pieris Pharmaceuticals do?

Pieris Pharmaceuticals Inc is a biotechnology company that focuses on the development of therapeutic antibodies. The company was founded in 2001 in Freising, Germany, and has since relocated its headquarters to Boston, USA. The company's history traces back to the research group of Professor Arne Skerra at the Technical University of Munich, which specialized in the development of new protein engineering technologies. Together with another biotech company, Swiss CYTHERIS SA, they eventually founded Pieris Pharmaceuticals Inc. The company received $10 million in funding in 2004 from international investors, including some German funds. Since then, the company has had several successful IPOs and has become one of the leading biotech companies in antibody research. The business model of Pieris Pharmaceuticals is based on the development and commercialization of antibodies that can be used as therapeutics for various diseases. The company combines its own research and development efforts with partnerships with other companies and organizations. The company's divisions include the development of antibodies for the treatment of cancer and immune-related diseases, the development of antibodies to combat infectious diseases, and the development of novel antibody platforms to generate broad antibody spectra. One of Pieris Pharmaceuticals' most successful products is the antibody PRS-343, which was developed as a therapeutic for HER2-positive breast cancer. A study showed that PRS-343, in combination with the chemotherapy drug Herceptin, has a higher efficacy than Herceptin alone. Another promising project is the development of an antibody for the treatment of tumors in the gastrointestinal tract. The substance PRS-276 is able to selectively attack and kill these cells due to its high affinity to the tumor antigen Claudin18.2. Overall, Pieris Pharmaceuticals Inc has launched numerous successful projects in recent years and has expanded its competitive position in the biotech industry. The company aims to closely collaborate with partners from the pharmaceutical industry to accelerate and optimize the development and commercialization of its products. Pieris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Pieris Pharmaceuticals's Employee Base

Pieris Pharmaceuticals's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Pieris Pharmaceuticals's operational capacity and future potential.

Year-to-Year Comparison

Assessing Pieris Pharmaceuticals's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Pieris Pharmaceuticals's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Pieris Pharmaceuticals’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Pieris Pharmaceuticals stock

How many employees does Pieris Pharmaceuticals have this year?

Pieris Pharmaceuticals has 114 undefined employees this year.

How many employees did Pieris Pharmaceuticals have compared to the previous year?

Compared to the previous year, Pieris Pharmaceuticals had 0% more employees.

What impact did the number of employees have on the company Pieris Pharmaceuticals?

The number of employees has a direct impact on the efficiency and productivity of Pieris Pharmaceuticals. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Pieris Pharmaceuticals?

The number of employees can also have an impact on investors of Pieris Pharmaceuticals, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Pieris Pharmaceuticals affect the company?

An increase in equity of Pieris Pharmaceuticals can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Pieris Pharmaceuticals's equity affect the company?

A reduction in equity of Pieris Pharmaceuticals can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Pieris Pharmaceuticals?

Some factors that can influence the equity of Pieris Pharmaceuticals include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Pieris Pharmaceuticals so important for investors?

The equity of Pieris Pharmaceuticals is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Pieris Pharmaceuticals influence the company?

The number of employees at Pieris Pharmaceuticals can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Pieris Pharmaceuticals evolved in recent years?

In recent years, the number of employees at Pieris Pharmaceuticals has changed by 0.

How many employees does Pieris Pharmaceuticals currently have?

Pieris Pharmaceuticals currently has 114 undefined employees.

Why is the number of employees important for investors of Pieris Pharmaceuticals?

The number of employees is important for investors of Pieris Pharmaceuticals as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Pieris Pharmaceuticals take to change the number of employees?

To change the number of employees, Pieris Pharmaceuticals can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Pieris Pharmaceuticals pay?

Over the past 12 months, Pieris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pieris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Pieris Pharmaceuticals?

The current dividend yield of Pieris Pharmaceuticals is .

When does Pieris Pharmaceuticals pay dividends?

Pieris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pieris Pharmaceuticals?

Pieris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Pieris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pieris Pharmaceuticals located?

Pieris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pieris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pieris Pharmaceuticals from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Pieris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Pieris Pharmaceuticals in the year 2023?

In the year 2023, Pieris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Pieris Pharmaceuticals pay out the dividend?

The dividends of Pieris Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Pieris Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Pieris Pharmaceuticals

Our stock analysis for Pieris Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pieris Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.